Estrogen receptor-positive (ER+) breast cancer treatment: Are multi-target compounds the next promising approach?

• Tipo: Outra Publicação em Revista Científica Internacional
• Data: 2020

Autores

Almeida, CF (Autor) Outra; Oliveira, A (Autor) Outra; Ramos, MJ (Autor) FCUP; Pedro A Fernandes (Autor) FCUP; Teixeira, N (Autor) Outra; Amaral, C (Autor) Outra

Revista

Título: Biochemical Pharmacology

Vol. 177

ISSN: 0006-2952

Editora: Elsevier

Indexação

ISI Web of Knowledge - 53 Citações

Scopus - 55 Citações

Outras Informações

ID Authenticus: P-00S-1J4

DOI: 10.1016/j.bcp.2020.113989

Abstract (EN): Endocrine therapy is currently the main therapeutic approach for estrogen receptor-positive (ER+) breast cancer, the most frequent subtype of breast cancer in women worldwide. For this subtype of tumors, the current clinical treatment includes aromatase inhibitors (AIs) and anti-estrogenic compounds, such as Tamoxifen and Fulvestrant, being AIs the first-line treatment option for post-menopausal women. Moreover, the recent guidelines also suggest the use of these compounds by pre-menopausal women after suppressing ovaries function. However, besides its therapeutic efficacy, the prolonged use of this type of therapies may lead to the development of several adverse effects, as well as, endocrine resistance, limiting the effectiveness of such treatments. In order to surpass this issues and clinical concerns, during the last years, several studies have been suggesting alternative therapeutic approaches, considering the function of aromatase, ER alpha and ER beta. Here, we review the structural and functional features of these three targets and their importance in ER+ breast cancer treatment, as well as, the current treatment strategies used in clinic, emphasizing the importance of the development of multi-target compounds able to simultaneously modulate these key targets, as a novel and promising therapeutic strategy for this type of cancer.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 14